Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Botswana opens consultations on proposed 33 percent hike now

    November 19, 2026

    PM Modi meets Prince and Princess of Wales for climate talks

    November 19, 2026

    Dubai Airports expects over 70 million guests in 2026

    November 18, 2026
    Facebook X (Twitter) Instagram
    • Home
    • Contact Us
    Arab NarrativeArab Narrative
    • Automotive
    • Business
    • Entertainment
    • Health
    • Luxury
    • Lifestyle
    • News
    • Sports
    • Technology
    • Travel
    Arab NarrativeArab Narrative
    Home » England launches revolutionary seven-minute cancer therapy
    Health

    England launches revolutionary seven-minute cancer therapy

    August 31, 2023
    Facebook Twitter Pinterest LinkedIn Tumblr Email

    NHS England is setting a global precedent as it becomes the first healthcare system worldwide to offer a seven-minute subcutaneous injection for cancer treatment, radically cutting conventional treatment times by up to 75%. The groundbreaking immunotherapy, known as atezolizumab or Tecentriq, received formal approval from the Medicines and Healthcare products Regulatory Agency (MHRA) and will be available to hundreds of eligible patients, freeing up considerable time and resources for oncology teams.

    England launches revolutionary seven-minute cancer therapy

    Dr. Alexander Martin, a consultant oncologist at West Suffolk NHS Foundation Trust, lauded the swift approval: “This monumental leap forward in cancer care not only makes the treatment more convenient for patients but also significantly boosts the capacity of our medical teams to treat additional patients throughout the day.” Previously, atezolizumab had to be administered intravenously — a process requiring up to an hour for some patients, particularly when veins were difficult to access.

    Manufactured by Genentech, a subsidiary of Roche, the transformative atezolizumab drug boosts a patient’s own immune system to identify and eradicate cancer cells. Marius Scholtz, Medical Director at Roche Products Limited, pointed out the stark contrast between the traditional and new methods: “The subcutaneous injection takes approximately seven minutes, a fraction of the 30 to 60 minutes typically needed for intravenous infusion.”

    NHS England estimates that the majority of the approximately 3,600 patients beginning atezolizumab treatment annually will transition to the new, time-efficient injection. The treatment is applicable to a variety of cancer types, including lung, breast, liver, and bladder. However, it is noted that patients who are also receiving intravenous chemotherapy in tandem with atezolizumab may continue with the longer, transfusion-based treatment.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026

    Ebola cases top 11,200 as Africa CDC warns of record outbreak

    November 16, 2026

    Yellow fever kills 18 across nine African nations, WHO says

    November 7, 2026
    Latest News

    Botswana opens consultations on proposed 33 percent hike now

    November 19, 2026

    PM Modi meets Prince and Princess of Wales for climate talks

    November 19, 2026

    Dubai Airports expects over 70 million guests in 2026

    November 18, 2026

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    Over 9 million visitors lift Tunisia tourism income 3.4%

    November 17, 2026

    Sheikh Mohamed receives Venezuela’s Delcy Rodríguez in Abu Dhabi

    November 17, 2026

    Etihad plans seven weekly Calgary flights as demand grows

    November 17, 2026
    © 2021 Arab Narrative | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.